Jan. 12 at 2:32 PM
@Proposition_Joe @FrankGelbert @Hoppanin when
$CCCC gets closer to market, its pipeline could produce billions if it results in a “safer” Pomalyst or Revlimid.
$ALT is also significantly undervalued (5-10x).
But
$TNXP standa alone - an approved asset that patients are benefiting from and could make billions, and the company is valued below cash 🤩
Buying the dips and holding these biotech beauties long. 💊 🐂
